{
    "clinical_study": {
        "@rank": "57195", 
        "acronym": "onceMRK", 
        "arm_group": [
            {
                "arm_group_label": "Reformulated Raltegravir", 
                "arm_group_type": "Experimental", 
                "description": "Reformulated raltegravir 1200 mg (2x 600 mg tablets) orally once daily plus placebo to raltegravir 1 tablet orally twice daily plus TRUVADA\u2122 orally once daily for 96 weeks"
            }, 
            {
                "arm_group_label": "Raltegravir", 
                "arm_group_type": "Active Comparator", 
                "description": "Raltegravir 400 mg tablet orally twice daily plus placebo to reformulated raltegravir 2 tablets orally once daily plus TRUVADA\u2122 orally once daily for 96 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the safety and efficacy of reformulated raltegravir (MK-0518) 1200 mg once daily\n      in combination with TRUVADA\u2122 versus raltegravir 400 mg twice daily in combination with\n      TRUVADA\u2122 in HIV-1 infected, treatment-naive participants. The primary hypothesis being\n      tested is that reformulated raltegravir 1200 mg once-daily is non-inferior to raltegravir\n      400 mg twice-daily, each in combination therapy with TRUVADA\u2122, as assessed by the proportion\n      of participants achieving HIV-1 ribonucleic acid (RNA) <40 copies/mL at Week 48."
        }, 
        "brief_title": "Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA\u2122 in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)", 
        "completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "HIV Infection", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  HIV-1 positive\n\n          -  Na\u00efve to antiretroviral therapy including investigational antiretroviral agents\n\n          -  Not of reproductive potential or, if of reproductive potential agrees to 1) true\n             abstinence, or 2) use of an acceptable method of birth control during the study\n\n        Exclusion Criteria:\n\n          -  Use of recreational or illicit drugs or has recent history of drug or alcohol abuse\n             or dependence\n\n          -  Has been treated for a viral infection other than HIV-1 (such as hepatitis B) with an\n             agent that is active against HIV-1 including but not limited to adefovir, tenofovir,\n             entecavir, emtricitabine, or lamivudine\n\n          -  Has documented or known resistance to raltegravir, emtricitabine, and/or tenofovir\n             before the first dose of study drug\n\n          -  Has participated in a study with an investigational compound or device within 30 days\n             or anticipates participating in such a study during this study\n\n          -  Has used systemic immunosuppressive therapy or immune modulators within 30 days or is\n             anticipated to need them during the study (short courses of corticosteroids are\n             allowed)\n\n          -  Requires or is anticipated to require any of the following prohibited medications\n             while in the study: phenobarbital, phenytoin, rifampin, rifabutin, or calcium,\n             magnesium and aluminum containing antacids, such as TUMS\u2122, Maalox\u2122 and Milk of\n             Magnesia\u2122\n\n          -  Has significant hypersensitivity or other contraindication to any of the components\n             of the study drugs\n\n          -  Has current, active diagnosis of acute hepatitis due to any cause\n\n          -  Is pregnant, breastfeeding, or expecting to conceive during the study\n\n          -  Female participant expecting to donate eggs or male participant expecting to donate\n             sperm during the study\n\n          -  Is or has a family member (spouse or children) who is investigational staff or\n             sponsor staff directly involved in this trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "750", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02131233", 
            "org_study_id": "0518-292"
        }, 
        "intervention": [
            {
                "arm_group_label": "Reformulated Raltegravir", 
                "description": "Reformulated raltegravir for once-daily administration", 
                "intervention_name": "Reformulated Raltegravir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Raltegravir", 
                "description": "Raltegravir for twice-daily administration", 
                "intervention_name": "Raltegravir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Reformulated Raltegravir", 
                    "Raltegravir"
                ], 
                "description": "Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label)", 
                "intervention_name": "TRUVADA\u2122", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Raltegravir", 
                "intervention_name": "Placebo to Reformulated Raltegravir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Reformulated Raltegravir", 
                "intervention_name": "Placebo to Raltegravir", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 29, 2014", 
        "location": {
            "contact": {
                "last_name": "German Medical Information Center", 
                "phone": "49 800 673 673 673"
            }, 
            "facility": {
                "address": {
                    "city": "Haar", 
                    "country": "Germany"
                }, 
                "name": "Merck Sharp & Dohme GmbH"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Reformulated Raltegravir 1200 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Each in Combination With TRUVADA\u2122, in Treatment-Na\u00efve HIV-1 Infected Subjects", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_official": {
            "affiliation": "Merck Sharp & Dohme Corp.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of Participants Achieving <40 copies/mL HIV-1 Ribonucleic Acid (RNA) at Week 48", 
            "safety_issue": "No", 
            "time_frame": "Week 48"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02131233"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in Cluster of Differentiation (CD4) Cell Count at Week 48", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 48"
            }, 
            {
                "measure": "Percentage of Participants Achieving <40 copies/mL HIV-1 RNA at Week 96", 
                "safety_issue": "No", 
                "time_frame": "Week 96"
            }, 
            {
                "measure": "Change from Baseline in CD4 Cell Count at Week 96", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 96"
            }, 
            {
                "measure": "Percentage of Participants with an Adverse Experience", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 48"
            }, 
            {
                "measure": "Percentage of Participants with a Drug-Related Adverse Experience", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 48"
            }, 
            {
                "measure": "Percentage of Participants with a Serious Adverse Experience", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 48"
            }, 
            {
                "measure": "Percentage of Participants with a Serious and Drug-Related Adverse Experience", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 48"
            }, 
            {
                "measure": "Percentage of Participants Discontinued from Drug Therapy Due to an Adverse Experience", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 48"
            }, 
            {
                "measure": "Percentage of Participants with an Adverse Experience", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 96"
            }, 
            {
                "measure": "Percentage of Participants with a Drug-Related Adverse Experience", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 96"
            }, 
            {
                "measure": "Percentage of Participants with a Serious Adverse Experience", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 96"
            }, 
            {
                "measure": "Percentage of Participants with a Serious and Drug-Related Adverse Experience", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 96"
            }, 
            {
                "measure": "Percentage of Participants Discontinued from Drug Therapy Due to an Adverse Experience", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 96"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}